China’s first mRna anti-Covid vaccine will enter phase 3 clinical trials, the last, in May. This was reported by China National Radio (Cnr), citing an exclusive telephone interview with Ying Bo, founder of the Suzhou Abogen Biosciences (AbogenBio) company who developed the product – called ARCoV – together with the Institute of Military Medicine of the Academy of Sciences and Walvax Biotechnology Co. Phase 2 testing, he said, is progressing smoothly and nearing completion. Phase 3 will therefore start next month and will be conducted abroad, in close collaboration with Chinese contract research organization Tigermed.
As of the third quarter of 2021, ARCoV’s annual production capacity will reach 120 million doses, added the founder of AbogenBio.